Luteolin Induced-growth inhibition and apoptosis of human esophageal squamous carcinoma cell line Eca109 cells in vitro

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5455-5461

  Wang, Ting Ting ^a   Wang, Shao Kang ^a   Huang, Gui Ling ^a   Sun, Gui Ju ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Apopotosis; Cell cycle arrest; Eca109; Esophageal cancr; Luteolin

Indexed keywords

EID: 84874033669     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5455     Document Type: Article

References (60)

1. Altieri DC (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 22, 8581-9.
2. Ashokkumar P, Sudhandiran G (2008). Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother, 62, 590-7.
3. Cai X, Ye T, Liu C, et al (2011). Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol in Vitro, 25, 1385-91.
4. Casagrande F, Darbon JM (2001). Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol, 61, 1205-15.
5. Chen Q, Liu SM, Chen JH, et al (2012). Luteolin Induces Mitochondria-dependent Apoptosis in Human Lung Adenocarcinoma Cell. Natl Prod Commun, 7, 29-32.
6. Cheng AC, Huang TC, Lai CS, et al (2005). Induction of apoptosis by luteolin through cleavage of Bcl-2 family in human leukemia HL-60 cells. Eur J Pharmacol, 509, 1-10.
7. Chiu FL, Lin JK (2008). Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate, 68, 61-71.
8. Choi AY, Choi JH, Yoon H, et al (2011). Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells. Eur J Pharmacol, 668, 115-26.
9. Doonan F, Cotter TG (2008). Morphological assessment of apoptosis. Methods, 44, 200-4.
10. Fan YH, Yuan JM, Wang RW, et al (2008). Alcohol, Tobacco and Diet in Relation to Esophageal Cancer: The Shanghai Cohort Study. Nutr Cancer, 60, 354-63.
11. Fotsis T, Pepper MS, Aktas E, et al (1997). Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res, 57, 2916-21.
12. Gao X, Cassidy A, Schwarzschild MA, et al (2012). Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology, 78, 1138-45.
13. Gao Y, Hu N, Han XY, et al (2011). Risk factors for esophageal and gastric cancers in Shanxi Province, China: A case-control study. Cancer Epidemiol, 35, E91-9.
14. Gehoff A, Basten O, Sprenger T, et al (2012). Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method. Am J Surg Pathol, 36, 202-13.
15. Globocan (2008). International Agency for Research on Cancer. (Version current at June 20, 2012).
16. Gorgoulis VG, Zacharatos PV, Manolis E, et al. (1998). Effects of p53 mutants derived from lung carcinomas on the p53- responsive element (p53RE) of the MDM2 gene. Brit J Cancer, 77, 374-84.
17. He D, Ma X, Chen Y, et al (2012). Luteolin inhibits pyrogallolinduced apoptosis through the extracellular signal-regulated kinase signaling pathway. FEBS J, 279, 1834-43.
18. He J, Zhang RG, DZ (1995). Clinical significance of c-myc gene in esophageal squamous cell carcinoma. Natl med J China, 75, 94-6.
19. Huang YT, Hwang JJ, Lee PP, et al (1999). Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Brit J Pharmacol, 128, 999-1010.
20. Ikeguchi M, Kaibara N (2002). survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Brit J Cancer, 87, 883-7.
21. Ikeguchi M, Yamaguchi K, Kaibara N (2003). Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumor Biol, 24, 40-5.
22. Joensuu K, Hagstrom J, Leidenius M, et al (2011). Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases-elevated Bmi-1 expression in late breast cancer relapses. Virchows Arch, 459, 31-9.
23. Jones GJ, Heiss NS, Veale RB, et al. (1993). Amplification and expression of the TGF-alpha, EGF recptor and c-myc genes in 4 human esophageal squamous cell carcinoma lines. Bioscience Rep, 13, 303-312.
24. Ju W, Wang X, Shi HL, et al (2007). A critical role of luteolininduced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappa B pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol, 71, 1381-8.
25. Kanda Y, Nishiyama Y, Shimada Y, et al (1994). Analysis of gene amplification and overexpression in human esophageal carcinoma cell lines. Int J Cancer, 58, 291-7.
26. Kato J, Kuwabara Y, Mitani M, et al (2001). Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer, 95, 92-5.
27. Kim MJ, Woo JS, Kwon CH, et al (2012). Luteolin induces apoptotic cell death through AIF nuclear translocation mediated by activation of ERK and p38 in human breast cancer cell lines. Cell Biol Int, 36, 339-44.
28. Knowles LM, Zigrossi DA, Tauber RA, et al (2000). Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer, 38, 116-22.
29. Ko WG, Kang TH, Lee SJ, et al (2002). Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells. Phytother Res, 16, 295-8.
30. Komiya K, Sueoka-Aragane N, Sato A, et al (2010). Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer. Lung Cancer, 69, 232-8.
31. Lee HJ, Wang CJ, Kuo HC, et al (2005). Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharm, 203, 124-31.
32. Lee LT, Huang YT, Hwang JJ, et al (2002). Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res, 22, 1615-27.
33. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31.
34. Lim DY, Jeong Y, Tyner AL, et al (2007). Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastr L, 292, G66-75.
35. Lim DY, Park JHY (2005). Luteolin inhibits cell proliferation by inducing cell cycle arrest in G1 and G2/M phases in HT-29 human colon cancer cells. Faseb J, 19, A1693-4.
36. Ma G, Yang CL, QuY, et al (2007). The flavonoid component isorhamnetin in vitro inhibits proliferation and induces apoptosis in Eca-109 cells. Chem Biol Interact, 167,153-60.
37. Malumbres M, Barbacid M (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer, 9, 153-66.
38. Massague J (2004). G1 cell-cycle control and cancer. Nature, 432, 298-306.
39. Master Z, Chaudhary A, Sutter TR, et al (2012). Effects of flavonoids on CYP1 expression in RL95-2 endometrial carcinoma cells. Food Chem, 133, 912-22.
40. Mayne ST, Risch HA, Dubrow R, et al (2001). Nutrient Intake and Risk of Subtypes of Esophageal and Gastric Cancer. Cancer Epidem Biomar, 10, 1055-62.
41. McCullough ML, Peterson JJ, Patel R, et al (2012). Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr, 95, 454-64.
42. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survivial-application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.
43. Nogata Y, Sakamoto K, Shiratsuchi H, et al (2006). Flavonoid composition of fruit tissues of citrus species. Biosci Biotech Bioch, 70, 178-92.
44. Ong CS, Zhou J, Ong CN, et al (2010). Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt- GSK-3beta-Cyclin D1 pathway. Cancer Lett, 298, 167-75.
45. Oze I, Matsuo K, Hosono S, et al (2010). Comparison between self-reported facial flushing after alcohol consumption and ALDH2 Glu504Lys polymorphism for risk of upper aerodigestive tract cancer in a Japanese population. Cancer Sci, 101, 1875-80.
46. Park CM, Jin KS, Cho CW, et al (2012). Luteolin inhibits inflammatory responses by downregulating the JNK, NF-?B, and AP-1 pathways in TNF-a activated HepG2 cells. Food Sci Biotech, 21, 279-83.
47. Pera M, Gallego R, Montagut C, et al (2012). Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol, 23, 664-70.
48. Prives C, Hall PA (1999). The p53 pathway. J Pathol, 187, 112-26.
49. Rosato A, Pivetta M, Parenti A, et al (2006). Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer, 119, 1717-22.
50. Sasaki N, Toda T, Kaneko T, et al (2003). Protective effects of flavonoids on the cytotoxicity of linoleic acid hydroperoxide toward rat pheochromocytoma PC12 cells. Chem Biol Interact, 145, 101-16.
51. Schwartz GK, Shah MA (2005). Targeting the cell cycle: A new approach to cancer therapy. J Clin Oncol, 23, 9408-21.
52. S Shi RX, Ong CN, Shen HM (2004). Luteolin sensitizes tumor necrosis factor-a-induced apoptosis in human tumor cells. Oncogene, 23, 7712-21.
53. Sivagami G, Vinothkumar R, Preethy CP, et al (2012). Role of hesperetin (a natural flavonoid) and its analogue on apoptosis in HT-29 human colon adenocarcinoma cell line - A comparative study. Food Chem Toxicol, 50, 660-71.
54. Su CC (2012). Tanshinone IIA potentiates the efficacy of 5-FU in Colo205 colon cancer cells in vivo through downregulation of P-gp and LC3-II. Exp Ther Med, 3, 555-9.
55. Sun MY, Han J, Duan JF, et al (2007). Novel antitumor activities of Kushen flavonoids in vitro and in vivo. Phytother Res, 21, 269-77.
56. Taylor WR, Stark GR (2001). Regulation of the G2/M transition by p53. Oncogene, 20, 1803-15.
57. Uehara A, Nakata M, Kitajima J, et al (2012). Internal and external flavonoids from the leaves of Japanese Chrysanthemum species (Asteraceae). Biochem Syst Ecol, 41, 142-9.
58. Veugelers PJ, Porter G A, Guernsey DL, et al (2006). Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus, 19, 321-8.
59. Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. Nature, 408, 307-10.
60. Wang LF, Lu A, Liu XX, et al (2011). The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via beta-catenindependent signaling. Oncol Rep, 26, 1149-56.